RxDoctor Payments Data

Sheetal Shah, MD

Ophthalmology · Atlanta, GANPI 1306042478

Payments from drug & device makers

$12,637in general payments, 2019–2025

Across 144 payments — averaging $87.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$8K
  • Harrow Eye, LLC$992
  • Oyster Point Pharma, Inc.$627
  • Bausch & Lomb Americas Inc.$515
  • Mallinckrodt Hospital Products Inc.$307
  • AbbVie$298
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$6,90055%
  • Food & beverage$5,71945%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,637 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$160,152
Medicare patients
596
Services billed
1,843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine124$169,823
MieboPerfluorohexyloctane/Pf158$138,260
XiidraLifitegrast77$92,390
Cyclosporine71$56,249
LumiganBimatoprost64$36,009
TyrvayaVarenicline Tartrate29$21,438
VevyeCyclosporine19$17,941
VyzultaLatanoprostene Bunod32$15,298
CequaCyclosporine11$12,973
Latanoprost345$5,263
SimbrinzaBrinzolamide/Brimonidine Tart15$4,759
Loteprednol Etabonate26$3,771
Brimonidine Tartrate38$2,997
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,319
Prednisolone Acetate60$2,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$515$245,948267 claims
AbbVieRestasis, Lumigan$298$205,832188 claims
Oyster Point Pharma, Inc.Tyrvaya$627$21,43829 claims
Harrow Eye, LLCVevye$992$17,94119 claims
Sun Pharmaceutical Industries Inc.Cequa$8,144$12,97311 claims
AlconSimbrinza$205$4,75915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →